New York (GenomeWeb)  GenomicVision announced today that it has extended its collaboration and commercialization agreement with Quest Diagnostics for the development of new biomarkers to improve the genetic detection of spinal muscular atrophy.

The companies are accelerating the pace of their collaboration with the goal of detecting SMA "2+0" carrier status. Identification of this rare form of mutation would lead to greater sensitivity in SMA screening, according to Genomic Vision.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.